Nivolumab (Opdivo▼), pembrolizumab (Keytruda▼): reports of organ transplant rejection

There have been reports of rejection of solid organ transplants in patients treated with nivolumab or pembrolizumab. Ipilimumab (Yervoy▼) may also interfere with immunosuppressive therapy, increasing the risk of graft rejection.